<DOC>
	<DOCNO>NCT02969798</DOCNO>
	<brief_summary>HYPOTHESIS : Impaired glucose tolerance ( IGT ) impair fast glucose ( IFG ) distinct pathophysiologic etiology . Therefore , therapeutic intervention design correct specific underlie pathogenic abnormality IGT IFG require optimally prevent progressive beta cell failure development overt type 2 diabetes .</brief_summary>
	<brief_title>Pre-diabetes Subject With Impaired Fasting Glucose ( IFG ) Impaired Glucose Tolerance ( IGT )</brief_title>
	<detailed_description>SPECIFIC AIMS : 1 . To examine effect follow pharmacologic intervention beta cell function , insulin sensitivity , glucose tolerance status individual isolate impaired glucose tolerance ( IGT ) : ( ) treatment renal Sodium-glucose co-transporter 2 ( SGLT2 ) inhibitor inhibitor , dapagliflozin ; ( ii ) treatment inhibitor dipeptidyl peptidase 4 , also DPP4 , saxagliptin ; ( iii ) treatment thiazolidinedione , pioglitazone ; ( iv ) treatment biguanide , metformin . 2 . To examine effect follow pharmacologic intervention beta cell function , insulin sensitivity , glucose tolerance status individual isolate impaired fasting glucose ( IFG ) : ( ) treatment renal SGLT2 inhibitor , dapagliflozin ; ( ii ) treatment DPP4 inhibitor , saxagliptin ; ( iii ) treatment thiazolidinedione , pioglitazone ; ( iv ) treatment biguanide , metformin . 3 . To examine effect follow pharmacologic intervention beta cell function , insulin sensitivity , glucose tolerance status individual combine impaired glucose tolerance ( IGT ) plus impaired fasting glucose ( IFG ) : ) treatment renal SGLT2 inhibitor , dapagliflozin ; ( ii ) treatment DPP4 inhibitor , saxagliptin ; ( iii ) treatment thiazolidinedione , pioglitazone ; ( iv ) treatment biguanide , metformin .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>NGT subject serve control match age , gender , ethnicity , BMI IGT IFG subject 1 . Male female subject age 18 65 year age , inclusive , Screening . 2 . FPG &lt; 100 mg/dl 2h PG &lt; 140 mg/dl 3 . BMI = 2440 kg/m2 ; 4 . Stable body weight ( ±4lbs ) precede 3 month 5 . Subjects evidence major organ system disease determine physical exam , history , screen laboratory data 6 . Females childbearing potential negative pregnancy test Screening Treatment visit , use one follow form contraception duration participation study ( i.e. , Followup 714 day post last dose ) : Oral contraceptive Injectable progesterone Subdermal implant Spermicidal foam/gel/film/cream/suppository Diaphragm spermicide Copper hormonal contain IUD Sterile male partner vasectomize &gt; 6 month predosing . 7 . Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . 8 . Subjects must willing able comply schedule visit , treatment , laboratory test study procedure . 1 . Recent ( i.e. , within three ( 3 ) month prior Screening ) evidence medical history unstable concurrent disease : documented evidence history clinically significant hematological , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , immunological , clinically significant neurological disease . 2 . Subjects family history diabetes first degree relative 3 . BMI le 24 great 40 kg/m2 4 . Unstable body weight ( change great ±4lbs precede 3 month 5 . Subjects participate excessively heavy exercise program 6 . Subject feeding/sleeping schedule different daytime feeding/night time sleep schedule 7 . Subjects take medication know alter glucose metabolism ( exception metformin and/or pioglitazone ) effect brain neurosynaptic function exclude . 8 . Subjects evidence major organ system disease determine physical exam , history , screen laboratory data 9 . Pregnant subject subject unwilling use birth control study enrollment 10 . Blood donation approximately 1 pint ( 500 mL ) within 8 week prior Screening . 11 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study 12 . Subjects hematuria exclude . 13 . Subjects evidence prior history heart failure exclude 14 . Subjects family history pancreatic , bladder , breast cancer exclude . 15 . Subjects history pancreatitis exclude . 16 . Subjects eGFR &lt; 60 ±5 ml/min.1.73m2 exclude . 17 . Subjects elevate serum creatinine ( &gt; 1.5 mg/dl males/1.4 mg/dl female ) exclude . 18 . Subjects history orthostatic hypotension ( &gt; 15/10 mmHg ) exclude . 19 . Subjects liver enzymes ( ALT , AST ) &gt; 3fold upper normal limit exclude . 20 . Subjects history hypersensitivity pioglitazone , dapagliflozin , Saxagliptin exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>